Table 1.
General characteristics of 31 patients
| Patient no. | Age | Gender | Location of primary tumor | TNM classification | Site of metastases | Pre-procedural NRS | Post-procedural NRS (6 months) | Size of lymph node metastasis (cm*cm) | Pre-treatments |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | M | NPC | IVT3N3M1 | L | 8 | 3 | 8*5 | Cisplatin + fluorouracil (4), radiotherapy (2) |
| 2 | 63 | M | NPC | IVT1N1M1 | L | 7 | 2 | 3*3 | Cisplatin + fluorouracil (4) |
| 3 | 65 | F | NPC | IVT2N3M1 | L | 7 | 2 | 6*3 | Cisplatin + fluorouracil (4) |
| 4 | 60 | M | NPC | IVT2N2M1 | L | 7 | 2 | 4*3 | Cisplatin + fluorouracil (4), radiotherapy (2), surgery (2) |
| 5 | 55 | F | NPC | IVT3N3M1 | R | 9 | 2 | 7*4 | |
| 6 | 61 | M | NPC | IVT2N1M1 | R | 9 | 3 | 5*2 | Cisplatin + fluorouracil (3) |
| 7 | 63 | F | NPC | IVT2N1M1 | L | 8 | 3 | 5*4 | Cisplatin + fluorouracil (3) |
| 8 | 54 | F | NPC | IVT1N3M1 | R | 7 | 3 | 6*3 | Radiotherapy (2) |
| 9 | 52 | M | NPC | IVT4N3M1 | L | 9 | 2 | 8*5 | Cisplatin + fluorouracil (4) surgery (2) |
| 10 | 70 | M | Tongue cancer | IVT1N2M1 | R | 8 | 2 | 3*3 | |
| 11 | 65 | M | Tongue cancer | IVT2N3M1 | L | 7 | 3 | 5*3 | Cisplatin vincristine methotrexate (3) |
| 12 | 72 | F | Tongue cancer | IVT2N2M1 | L | 8 | 2 | 5*4 | |
| 13 | 68 | M | Tongue cancer | IVT2N3M1 | R | 6 | 2 | 4*4 | Cisplatin vincristine methotrexate (3) |
| 14 | 74 | M | Tongue cancer | IVT2N3M1 | L | 8 | 2 | 5*4 | Radiotherapy (2) |
| 15 | 71 | F | Tongue cancer | IVT2N3M1 | R | 7 | 1 | 4*3 | |
| 16 | 69 | F | Tongue cancer | IVT2N3M1 | R | 7 | 2 | 4*4 | Cisplatin vincristine methotrexate (3) |
| 17 | 67 | F | Tongue cancer | IVT3N3M1 | L | 9 | 3 | 6*7 | Cisplatin vincristine methotrexate (3) |
| 18 | 75 | M | Laryngocarcinoma | IVT2N3M1 | R | 9 | 2 | 5*4 | Surgery (2) |
| 19 | 69 | M | Laryngocarcinoma | IVT3N2M1 | R | 8 | 3 | 7*4 | |
| 20 | 70 | M | Laryngocarcinoma | IVT2N3M1 | R | 9 | 2 | 5*3 | Radiotherapy (2) |
| 21 | 73 | M | Laryngocarcinoma | IVT2N3M1 | R | 8 | 2 | 6*5 | |
| 22 | 70 | F | Laryngocarcinoma | IVT2N2M1 | R | 9 | 2 | 4*4 | Surgery (2) |
| 23 | 75 | M | Maxillary sinus carcinoma | IVT2N3M1 | R | 8 | 2 | 6*4 | Carboplatin (4) |
| 24 | 70 | M | Maxillary sinus carcinoma | IVT2N2M1 | R | 7 | 2 | 5*4 | Cisplatin (3) |
| 25 | 51 | F | Maxillary sinus carcinoma | IVT2N3M1 | L | 6 | 2 | 6*4 | Cisplatin (3) |
| 26 | 75 | F | Thyroid cancer | IVT2N1M1 | R | 7 | 8 | 6*5 | Radiotherapy (2) |
| 27 | 57 | M | Thyroid cancer | IVT2N1M1 | L | 8 | 2 | 5*5 | |
| 28 | 61 | M | Thyroid cancer | IVT3N1M1 | R | 9 | 2 | 5*3 | |
| 29 | 59 | F | Thyroid cancer | IVT2N1M1 | L | 7 | 2 | 4*4 | Surgery (2) |
| 30 | 48 | M | Thyroid cancer | IVT3N1M1 | L | 7 | 2 | 5*4 | |
| 31 | 74 | M | Thyroid cancer | IVT2N1M1 | L | 8 | 2 | 6*5 | Surgery (2) |
M male, F female, L left cervical lymph node, R right cervical lymph node, NPC nasal pharyngeal cancer